Overview
Rybrevant Faspro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that has specific epidermal growth factor receptor (EGFR) mutations (variations). It is approved for first-line treatment in combination with lazertinib or with chemotherapy for tumors with EGFR exon 19 deletions, exon 21 L858R substitutions, or exon 20 insertion mutations, as identified by an FDA-approved test. Rybrevant Faspro is also approved for use alone in people with EGFR exon 20 insertion mutations whose cancer progressed after platinum-based chemotherapy. Rybrevant Faspro is also known by its drug name, amivantamab and hyaluronidase-lpuj.

Rybrevant Faspro is a biologic medicine made from a combination of a bispecific antibody and an enzyme. The antibody targets two proteins (EGFR and MET) involved in the growth of lung cancer cells, while the enzyme (hyaluronidase) helps the drug absorb into the body when given under the skin.

How do I take it?
Prescribing information states that Rybrevant Faspro is given by subcutaneous (under the skin) injection in the abdomen over approximately five minutes. It can be used alone or in combination with other drugs like lazertinib, carboplatin, and pemetrexed, depending on the type of EGFR mutation and treatment history. The dosing schedule is either every two weeks or every three weeks, depending on the treatment plan. Rybrevant Faspro should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Rybrevant Faspro vary depending on how it is used. When given in combination with lazertinib, common side effects include rash, nail problems, muscle and joint pain, fatigue, mouth sores, edema (swelling), nausea, diarrhea, vomiting, constipation, reduced appetite, and headache.

Common changes in blood test results included low levels of lymphocytes, sodium, potassium, albumin, and hemoglobin, as well as low platelet counts. Increased levels of liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) may also occur.

Fewer side effect data are currently available for Rybrevant Faspro when used alone or in combination with chemotherapy, but based on related studies of intravenous amivantamab, possible side effects may include infusion-related reactions, dry skin, COVID-19, and blood clotting problems.

Rare but serious side effects may include allergic reactions, lung inflammation (pneumonitis), severe rash, eye problems, and increased risk of blood clots. Rybrevant Faspro may also harm an unborn baby, so effective birth control is recommended during treatment.

For more information about this treatment, visit:
Rybrevant Faspro (Amivantamab And Hyaluronidase-Lpuj) Injection, for Subcutaneous Use — Janssen Biotech